PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 23, 2024Transplant Infectious Disease2 citations

Infections following chimeric antigen receptor T cell therapy: 2018–2022

View Full Paper
VKVishakh C KeriLMLea MondayJRJahanavi M. Ramakrishna

Key Points

Key points are not available for this paper at this time.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is an emerging therapeutic modality for relapsed and refractory hematological malignancies. Infectious complications following CAR T-cell therapy are not well defined.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Keri et al. (2024) studied this question.

synapsesocial.com/papers/68e579d1b6db6435875196f3https://doi.org/10.1111/tid.14376
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies2024 · 94 citations
  2. 2Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention2026 · 2 citations
  3. 3Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults2024 · 1 citations
  4. 4Chimeric Antigen Receptor Immunotherapy for Infectious Diseases: Current Advances and Future Perspectives2025
  5. 5Chimeric Antigen Receptors T Cells (CAR T) Therapy2024